Get the Stockscreener App
11.93
7.96%
0.88
Tandem Diabetes Care Inc stock is traded at $11.93, with a volume of 2.17M.
It is up +7.96% in the last 24 hours and down -22.08% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$11.05
Open:
$11.18
24h Volume:
2.17M
Relative Volume:
1.16
Market Cap:
$806.10M
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-5.7081
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
+10.26%
1M Performance:
-22.08%
6M Performance:
-61.52%
1Y Performance:
-71.92%
1-Day Range:
$11.16
$12.08
1-Week Range:
$10.25
$12.08
52-Week Range:
$9.98
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
11.93 | 732.45M | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Upgrade | Citigroup | Sell → Neutral |
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Sirius XM, Lovesac, Rogers, Tandem Diabetes, and Altice Shares Are Falling, What You Need To Know - Yahoo Finance
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Tandem Diabetes: Lowering Our Fair Value Estimate Significantly on Signs of Softness - Morningstar
Commercial and Competitive Headwinds to Delay Tandem's Shift to Positive Profits - Morningstar
Diabetes warning issued over insulin pump error - MSN
Tandem Diabetes Care Inc. Forms Bullish Flag — Upside AheadJuly 2025 Setups & Fast Moving Market Watchlists - metal.it
Software correction coming for faulty insulin pumps - MSN
Why Tandem Diabetes Care Inc. stock attracts strong analyst attentionJuly 2025 Rallies & Weekly High Return Forecasts - thegnnews.com
What is Tandem Diabetes Care Inc.’s valuation compared to sector - kangso.co.kr
What’s the recovery path for long term holders of Tandem Diabetes Care Inc. - Newser
Will Tandem Diabetes Care Inc. continue its uptrendCPI Data & Weekly Return Optimization Plans - Newser
Reversal indicators forming on Tandem Diabetes Care Inc. stockStop Loss & Free Weekly Watchlist of Top Performers - Newser
Technical analysis overview for Tandem Diabetes Care Inc. stockMarket Performance Recap & Growth Oriented Trading Recommendations - Newser
Trend analysis for Tandem Diabetes Care Inc. this week2025 Earnings Impact & Weekly Top Gainers Trade List - Newser
PNC Financial Services Group Inc. Sells 3,004 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Relative strength of Tandem Diabetes Care Inc. in sector analysisRate Hike & High Accuracy Buy Signal Tips - Newser
Analyzing drawdowns of Tandem Diabetes Care Inc. with statistical toolsWeekly Volume Report & Capital Protection Trade Alerts - Newser
Price momentum metrics for Tandem Diabetes Care Inc. explainedTrade Volume Report & Weekly Return Optimization Alerts - Newser
What makes Tandem Diabetes Care Inc. stock price move sharplyOptions Play & High Accuracy Trade Signal Alerts - Newser
What does recent volatility data suggest for Tandem Diabetes Care Inc.July 2025 Action & Free Long-Term Investment Growth Plans - Newser
Watch for Bullish Crossover in Tandem Diabetes Care Inc.July 2025 Weekly Recap & Accurate Trade Setup Notifications - sundaytimes.kr
Published on: 2025-08-15 18:45:11 - kangso.co.kr
Tandem Diabetes upgraded at Citi on risk-reward setup - MSN
Will Tandem Diabetes Care Inc. outperform the marketJuly 2025 Technicals & Technical Pattern Alert System - Newser
Tandem Diabetes Care’s SWOT analysis: stock faces challenges amid competitive pressures - Investing.com Australia
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - The Globe and Mail
Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - The Globe and Mail
FDA Warns of Dangerous Error in Popular Insulin Pump Linked to 700 Adverse Events - Prevention
Intraday Charts Show Spike in Tandem Diabetes Care Inc. ActivityDay Trade & High Win Rate Trade Tips - thegnnews.com
FDA clearances: Imris, Daxor Corp., Tandem Diabetes Care - Modern Healthcare
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of “Hold” by Brokerages - Defense World
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The Globe and Mail
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know - Yahoo Finance
Diabetes Warning Issued Over Insulin Pump Error - Newsweek
Tandem Diabetes Care: Strategic Growth Potential and Market Expansion Drive Buy Rating - TipRanks
5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings Call - Yahoo Finance
Published on: 2025-08-13 16:11:40 - 선데이타임즈
Lake Street Capital Downgrades Tandem Diabetes Care (NASDAQ:TNDM) to Hold - Defense World
Tandem Diabetes Care: Navigating Volatility and Innovation in a Polarized Market - AInvest
Tandem Diabetes' Recent Surge: Is This the Start of a Long-Term Rally or a Short-Lived Rebound? - AInvest
Tandem Diabetes Care Shares Rise After Upgrade From Citigroup - MarketScreener
Tandem Diabetes upgraded to Neutral by Citi, citing shift in risk-reward setup - AInvest
Tandem Diabetes stock upgraded at Citi (TNDM:NASDAQ) - Seeking Alpha
Tandem Diabetes at Canaccord Conference: Strategic Shifts and Market Focus - Investing.com Canada
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - Yahoo Finance
Tandem Diabetes Care shares rise 7.46% intraday after Citigroup upgrades stock to Neutral. - AInvest
Tandem Diabetes Care Stock (TNDM) Opinions on Q2 2025 Earnings Miss - Quiver Quantitative
Citigroup Upgrades Tandem Diabetes Care to Neutral From Sell, Adjusts Price Target to $10.35 From $10 - MarketScreener
Citi Upgrades Tandem Diabetes Care to Neutral, Raises PT to $10.35 - AInvest
TNDM Q2 Deep Dive: Margin Pressures and Strategic Shifts Offset Sales Growth - ca.finance.yahoo.com
Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 6.6% on Analyst Downgrade - Defense World
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tandem Diabetes Care Inc Stock (TNDM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morrison Susan | EVP & Chief Admin. Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,600 |
0 |
39,376 |
| Sheridan John F | PRESIDENT & CEO |
Aug 15 '25 |
Option Exercise |
0.00 |
11,453 |
0 |
115,001 |
| Carpenter Rick | Chief Technology Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,335 |
0 |
22,824 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 15 '25 |
Option Exercise |
0.00 |
2,998 |
0 |
36,258 |
| Hansen Shannon Marie | EVP & Chief Legal Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
3,065 |
0 |
19,102 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,600 |
0 |
1,795 |
| Sheridan John F | PRESIDENT & CEO |
Aug 11 '25 |
Buy |
10.23 |
10,000 |
102,318 |
106,327 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 08 '25 |
Buy |
10.89 |
13,720 |
149,404 |
25,580 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer |
Jul 15 '25 |
Option Exercise |
0.00 |
14,545 |
0 |
25,254 |
| Carpenter Rick | Chief Technology Officer |
Jun 16 '25 |
Option Exercise |
0.00 |
406 |
0 |
21,426 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):